Latest news with #JoséCastillo
Business Wire
a day ago
- Business
- Business Wire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Under the agreement, Quantoom will have access to TriLink's CleanCap® mRNA capping technology for integration in its Ntensify® (sa)mRNA production platform to help accelerate the RNA production process and make life-saving therapeutics and vaccines more accessible to patients worldwide. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. TriLink's CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when compared to legacy capping methods. Under this agreement, TriLink will supply its patented CleanCap technology for use in Quantoom's (sa)mRNA production platform, allowing customers to benefit from the industry's leading capping technology to develop their unique (sa)mRNA drugs using the Ntensify platform through clinical development phases. "Strengthening global health against infectious diseases requires strong industry partnerships," said Becky Buzzeo, Chief Commercial Officer at Maravai. "We're excited for the Quantoom production platform to incorporate TriLink's CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources." Since its debut in 2017, TriLink's CleanCap capping technology has transformed the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. 'We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences. "By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need." About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans. For more information about TriLink, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About Quantoom Biosciences Quantoom Biosciences is a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics. Its N-Force TM toolbox relies on 3 core elements to turn any antigen into a (sa)mRNA-LNP drug product: Ncode TM for sequence design and optimization, Ntensify ® for RNA production and Ncapsulate ® for RNA-LNP formulation. Launched in 2023, the Ntensify solution enables fully integrated, scalable RNA production by combining processes, equipment, reagent mixes, and disposables and has gained global adoption, being recognized for performance and ease-of-use. Beyond technology, Quantoom Biosciences assists its partners by providing extensive enabling solutions, ranging from strategic R&D partnerships to sequence design & optimization.
Yahoo
26-05-2025
- Sport
- Yahoo
Pachuca eye Palavecino for Club World Cup
This article was translated into English by Artificial Intelligence. You can read the original version in 🇪🇸 here. Pachuca is going through challenging times with their coach Guillermo Almada, just three weeks before the start of the 2025 Club World Cup, their next major international challenge. In this tournament, they will face Real Madrid again, who defeated them 3-0 in the final of the 2024 Intercontinental Cup. Without focusing on Liga MX, the Tuzos are actively seeking reinforcements to tackle Group H, where they will face Real Madrid, Al-Hilal from Saudi Arabia, and RB Salzburg from Austria. On Saturday, they confirmed the arrival of José Castillo, a fullback returning after his stint with Chivas. Now, the target is Agustín Palavecino, a midfielder from Necaxa. According to César Luis Merlo, the Argentine is interested in joining Pachuca for the World Cup, but the club must negotiate with the Rayos for his temporary loan. Palavecino has played 39 official matches with Necaxa, scoring nine goals and providing six assists, averaging a goal contribution every 90 minutes. Although Necaxa does not want to part with their key players, like Diber Cambindo or Paradela, a short-term loan could be feasible. 📸 JULIO CESAR AGUILAR - AFP or licensors
Associated Press
12-05-2025
- Sport
- Associated Press
Diamondbacks promote top prospect Jordan Lawlar after hot start in Triple-A
SAN FRANCISCO (AP) — The Arizona Diamondbacks called up top prospect Jordan Lawlar on Monday as they fight for position in the National League West division. The D-backs also reinstated reliever Kendall Graveman to the active roster. The veteran right-hander hasn't pitched this season because of a strained right lumbar. The 22-year-old Lawlar likely will play a variety of positions for Arizona, including second base, shortstop and third. He was hitting .336 with six homers, 31 RBIs and 13 stolen bases at Triple-A Reno. The Diamondbacks had a 21-20 record entering Monday's game in San Francisco, which was fourth in NL West behind the Los Angeles Dodgers, San Diego Padres and Giants. Lawlar played in the big leagues briefly in 2023, helping the Diamondbacks in a limited role during their surprise run to the World Series. He hit .129 in 31 at-bats. The No. 6 overall pick in the 2021 amateur draft missed much of last season with injuries. To make room on the roster, the D-backs designated infielder Garrett Hampson and reliever José Castillo for assignment. ___ AP MLB:
